【摘要】：目的:為抗凝血藥臨床合理使用提供參考。方法:從醫(yī)院信息系統(tǒng)提取我院2013-2015年住院患者抗凝血藥使用的醫(yī)囑信息,計算和分析該類藥品的銷售金額、用藥頻度(DDDs)、日均費用(DDC)以及各科室使用情況。結(jié)果:2013-2015年,低分子肝素鈣注射液(6 000 AXa IU)、依諾肝素鈉注射液(6 000 AXa IU)、達肝素鈉注射液(5 000 IU)和利伐沙班片(10 mg)的金額比呈上升趨勢,那屈肝素鈣注射液(6 150、4 100 AXa IU)和磺達肝癸鈉注射液(2.5 mg)的金額比呈下降趨勢。那屈肝素鈣注射液(4 100 AXa IU)、達肝素鈉注射液(5 000 IU)和依諾肝素鈉注射液(6 000 AXa IU)的DDDs位居前3位。利伐沙班片的DDC值最高,為167.60~180.25元。那屈肝素鈣注射液(6 150、4 100 AXa IU)、低分子肝素鈣注射液(6 000 AXa IU)、磺達肝癸鈉注射液(2.5 mg)和華法林鈉片(3 mg)3年內(nèi)使用同步性較好,B/A值為0.50~1.50。血管外科的利伐沙班銷售金額及使用率均居第1位。結(jié)論:結(jié)合醫(yī)院疾病譜及各種藥品的特點和不良反應(yīng),我院近3年抗凝血藥使用趨于合理,但其使用情況仍應(yīng)作為常規(guī)藥學(xué)監(jiān)測內(nèi)容。
[Abstract]:Objective: to provide reference for clinical rational use of anticoagulant. Methods: the information of anticoagulant used by inpatients in our hospital from 2013 to 2015 was extracted from hospital information system, and the sales amount of anticoagulant drugs, the average daily cost of (DDDs), and the use of anticoagulant drugs in various departments were calculated and analyzed. Results: from 2013 to 2015, the amount ratio of low molecular weight heparin calcium injection (6000 AXa IU), enoheparin sodium injection (6000 AXa IU),) heparin sodium injection (5000 IU) and rivasaban tablet (10 mg) showed an upward trend. The amount ratio of Naproheparin calcium injection (6 150, 4 100 AXa IU) and sulfondachan decyl sodium injection (2. 5 mg) showed a downward trend. The DDDs of Nadroheparin calcium injection (4 100 AXa IU),) and enoheparin sodium injection (6 000 AXa IU) were in the top three. The DDC value of rivasaban tablets was the highest (167.60 鈮，

本文編號：2486334